...
首页> 外文期刊>Journal of the Chinese Medical Association: JCMA >Cidofovir injection for recurrent laryngeal papillomatosis.
【24h】

Cidofovir injection for recurrent laryngeal papillomatosis.

机译:西多福韦注射液用于复发性喉乳头状瘤病。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Recurrent laryngeal papillomatosis is caused by the human papilloma virus and characterized by multiple exophytic lesions of the vocal tract; it is a benign disease, but one that tends to recur after removal of growths. Due to the nature of the disease, alternative treatment strategies have focused on antiviral injection at lesion sites that eliminate repeated surgical procedures. The purpose of this study was to evaluate the efficacy of cidofovir injection following initial papilloma excision with a microdebrider. METHODS: Cidofovir injections (at a concentration of 7.5 mg/mL) were conducted in 5 patients (1 child; 4 adults). The injection number per patient varied from 2 mL to 6 mL. Repeated cidofovir injections were indicated only if recurrent or newly grown lesions were found in any of 3-week follow-up visits. RESULTS: Short-term complete remission was observed with different duration, from 11 to 21 weeks, following initial 2 to 3 cidofovir injections. All patients relapsed eventually, and their recurrent lesions were not successfully eradicated by repeated cidofovir injection. One patient's prognosis was complicated by scarring of both vocal cords. CONCLUSION: Surgical excision combined with cidofovir injection failed to prevent relapsing laryngeal papillomatosis. Once lesions recurred, repeated cidofovir injections alone were not able to achieve complete remission, although these procedures might be helpful in lessening the severity of the clinical course. Further studies in determining the dosage, duration of injection, and more long-term follow-up are required to clarify the efficacy of cidofovir for the treatment of recurrent laryngeal papillomatosis.
机译:背景:喉返乳头状瘤病是由人乳头瘤病毒引起的,其特征是声带多发外生性病变。它是一种良性疾病,但在去除生长后往往会复发。由于该疾病的性质,替代治疗策略集中于在病灶部位进行抗病毒注射,以消除重复的手术程序。这项研究的目的是评估使用微清创术最初切除乳头状瘤后西多福韦注射的疗效。方法:西多福韦注射液(浓度为7.5 mg / mL)在5例患者(1名儿童; 4名成人)中进行。每位患者的注射数量从2 mL到6 mL不等。只有在3周的随访中发现复发或新出现的病灶时,才建议重复西多福韦注射。结果:在最初2至3次西多福韦注射后,在11至21周的不同持续时间观察到短期完全缓解。所有患者最终均复发,并且通过反复注射西多福韦未能成功根除其复发性病变。两条声带疤痕使一名患者的预后复杂化。结论:手术切除联合西多福韦不能预防复发性喉乳头状瘤病。一旦病灶复发,尽管重复这些步骤可能有助于减轻临床病程的严重程度,但单用重复的西多福韦注射液并不能完全缓解。需要进一步研究以确定剂量,注射持续时间和更长期的随访,以阐明西多福韦在治疗喉返乳头状瘤病中的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号